Stock Events

Stock Events

Ensysce Biosciences 

$0.000800
36
+$0.00+0% Monday 19:53

Statistics

Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.0008
Volume
42,199
Avg. Volume
-
Mkt Cap
12,292.42
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.02
-1.66
-0.3
1.05
Expected EPS
-0.5
Actual EPS
N/A

Financials

-200.83%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.07MRevenue
-10.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENSCW. It's not an investment recommendation.
NVIDIA
9
NVDA
Alphabet
8
GOOGL
Microsoft
7
MSFT
Legal & General Group
7
LGEN.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap8.66B
Alkermes plc focuses on central nervous system (CNS) diseases, including treatments for addiction, which competes with Ensysce's pain management and overdose protection technologies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries Limited offers generic and specialty medicines, including pain management solutions that directly compete with Ensysce's product offerings.
Collegium Pharmaceutical
COLL
Mkt Cap1.14B
Collegium Pharmaceutical, Inc. specializes in pain management, offering products that could be alternatives to Ensysce's abuse-deterrent formulations.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops medications for pain management, competing in the same market as Ensysce.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie Inc. has a strong portfolio in CNS and pain management, including therapies that could compete with Ensysce's products.
Novartis
NVS
Mkt Cap293.94B
Novartis AG offers a wide range of healthcare solutions, including pain management drugs that compete with Ensysce's pipeline.
Pacira BioSciences
PCRX
Mkt Cap1B
Pacira BioSciences, Inc. specializes in non-opioid pain management solutions, offering alternatives to Ensysce's opioid-based treatments.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.81B
Supernus Pharmaceuticals, Inc. focuses on CNS diseases, including treatments for conditions that may require pain management solutions competing with Ensysce.

About

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Show more...
CEO
Dr. D. Lynn Kirkpatrick Ph.D.
Employees
10
Country
United States
ISIN
US2936025046

Listings

OTCM
US
ENSCW
XNAS
US
ENSC
BOATS
BOATS
ENSC.BOATS

0 Comments

Share your thoughts

FAQ

What is Ensysce Biosciences stock price today?▼
The current price of ENSCW is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Ensysce Biosciences stock price performance more closely on the chart.
What is Ensysce Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Ensysce Biosciences stocks are traded under the ticker ENSCW.
What is Ensysce Biosciences market cap?▼
Today Ensysce Biosciences has the market capitalization of 12,292.42
When is the next Ensysce Biosciences earnings date?▼
Ensysce Biosciences is going to release the next earnings report on August 19, 2026.
What were Ensysce Biosciences earnings last quarter?▼
ENSCW earnings for the last quarter are -0.52 USD per share, whereas the estimation was -0.73 USD resulting in a +28.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ensysce Biosciences revenue for the last year?▼
Ensysce Biosciences revenue for the last year amounts to 5.07M USD.
What is Ensysce Biosciences net income for the last year?▼
ENSCW net income for the last year is -10.18M USD.
How many employees does Ensysce Biosciences have?▼
As of July 19, 2026, the company has 10 employees.
In which sector is Ensysce Biosciences located?▼
Ensysce Biosciences operates in the Health & Wellness sector.
When did Ensysce Biosciences complete a stock split?▼
The last stock split for Ensysce Biosciences was on December 06, 2024 with a ratio of 1:15.
Where is Ensysce Biosciences headquartered?▼
Ensysce Biosciences is headquartered in La Jolla, United States.